33 terminated. 33 Phase 3, 6 Phase 2.
By phase and status
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Trials (filtered) newest first · largest first
All 33 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)
QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | 5 | 2021-12-15 | 2024-08-07 |
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | 7 | 2021-12-08 | 2024-07-12 |
Effectiveness of Periocular Drug Injection in CATaract Surgery
Bromfenac, Dexamethasone, Triamcinolone Acetonide - Macular Edema, Cystoid Macular Edema | Phase 3 | Terminated | 628 | 2021-10-13 | 2024-11-04 |
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
KSI-301, Sham injection - Non-proliferative Diabetic Retinopathy | Phase 3 | Terminated | 253 | 2021-09-07 | 2024-09-05 |
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
2.0 mg OPT-302, 2.0 aflibercept, Sham - Neovascular Age-related Macular Degeneration | Phase 3 | Terminated | 998 | 2021-03-12 | 2025-08-05 |
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
KSI-301, Aflibercept, Sham Procedure - Diabetic Macular Edema | Phase 3 | Terminated | 459 | 2020-09-30 | 2024-08-22 |
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
KSI-301, Aflibercept, Sham Procedure - Diabetic Macular Edema | Phase 3 | Terminated | 460 | 2020-09-30 | 2024-08-22 |
Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF
intravitreal injection of Conbercept - Uveitis, Macular Edema | Phase 2 / Phase 3 | Terminated | 5 | 2019-10-12 | 2022-10-25 |
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
KSI-301, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 2 / Phase 3 | Terminated | 559 | 2019-10-08 | 2024-07-18 |
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection - Central Retinal Vein Occlusion | Phase 3 | Terminated | 493 | 2019-07-03 | 2023-01-30 |
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection - Branch Retinal Vein Occlusion | Phase 3 | Terminated | 450 | 2019-07-02 | 2023-01-30 |
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 3 | Terminated | 535 | 2018-10-30 | 2023-01-30 |
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin - Macular Edema, Retinal Vein Occlusion | Phase 3 | Terminated | 325 | 2018-03-05 | 2021-04-23 |
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept - Macular Edema, Retinal Vein Occlusion | Phase 3 | Terminated | 460 | 2017-01-31 | 2021-04-14 |
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Lampalizumab - Geographic Atrophy | Phase 3 | Terminated | 994 | 2016-07-21 | 2019-03-06 |
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Lampalizumab, Sham Comparator - Geographic Atrophy | Phase 3 | Terminated | 975 | 2014-10-06 | 2019-10-15 |
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Lampalizumab, Sham - Geographic Atrophy | Phase 3 | Terminated | 906 | 2014-09-18 | 2019-06-26 |
Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
Ranibizumab 0.5mg - Macular Edema, Macular Degeneration | Phase 3 | Terminated | 31 | 2014-05-19 | 2020-10-22 |
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
E10030, bevacizumab or aflibercept, E10030 sham injection - Age-Related Macular Degeneration | Phase 3 | Terminated | 645 | 2014-05-01 | 2024-10-31 |
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
E10030, ranibizumab, E10030 sham intravitreal injection - Age-Related Macular Degeneration | Phase 3 | Terminated | 627 | 2013-08-01 | 2024-10-30 |
Showing 20 of 33. Sign in to see all of them.
Narrower conditions
Macular Degeneration (16) · Macular Edema (12) · Vision Disorders (9) · Eye Diseases (8) · Retinal Diseases (8) · Choroidal Neovascularization (6) · Diabetic Retinopathy (5) · Retinal Vein Occlusion (5) · Diabetes Mellitus (4) · Geographic Atrophy (4) · Retinitis Pigmentosa (3) · Vision, Low (3) · Eye Abnormalities (2) · Eye Diseases, Hereditary (2)
Broader conditions
Eye Diseases (25) · Retinal Diseases (25) · Pathological Conditions, Signs and Symptoms (15) · Macular Degeneration (13) · Cardiovascular Diseases (10) · Nervous System Diseases (10) · Vascular Diseases (10) · Neurologic Manifestations (9) · Sensation Disorders (9) · Signs and Symptoms (9) · Uveal Diseases (7) · Choroid Diseases (6) · Endocrine System Diseases (6) · Eye Diseases, Hereditary (6)
Interventions
aflibercept (8) · salicylhydroxamic acid (8) · Ranibizumab (7) · E10030 aptamer (3) · Triamcinolone Acetonide (3) · brolucizumab (3) · lampalizumab (3) · Bevacizumab (2) · Intravitreal Injections (2) · Triamcinolone (2) · AL 3789 (1) · Alprostadil (1) · Dexamethasone (1) · Infliximab (1) · Predictive Value of Tests (1)
Sponsors
Kodiak Sciences Inc (4) · Novartis Pharmaceuticals (4) · Alcon Research (3) · Hoffmann-La Roche (3) · Ophthotech Corporation (3) · Clearside Biomedical, Inc. (2) · Laboratoires Thea (2) · Asociación para Evitar la Ceguera en México (1) · Genaera Corporation (1) · Helse Stavanger HF (1) · Luigi Rondas (1) · Novartis (1) · OPKO Health, Inc. (1) · Opthea Limited (1) · Peking Union Medical College Hospital (1)
Countries
United States (23) · Germany (14) · Spain (13) · Hungary (12) · Italy (12) · France (11) · Poland (11) · Slovakia (11) · United Kingdom (11) · Austria (10) · Australia (9) · Canada (9) · Czechia (8) · Denmark (8) · Netherlands (8)
Top investigators
Pablo Velazquez-Martin, MD (4) · Daniel Janer, MD (1) · Denis O'Shaughnessy, Ph.D. (1) · Henry Ferreyra, MD (1) · Johan Seland, PhD (1) · Nienke Visser, Dr. (1) · Petros Sfikakis, MD (1) · Sally Scheib, Sr. Clinical Lead (1) · Terry Wiernas, PhD (1)
Results publications
PMID 30957581, PMID 29801123, PMID 32199866, PMID 37314061, PMID 37869030, PMID 38900484, PMID 39102242, PMID 39758130, PMID 42668567, PMID 20413522, PMID 22424834, PMID 25079064, PMID 27388251, PMID 33383315
NIH funding
2014 (2), 2018 (2), 2005 (1), 2016 (1), 2019 (1)